Clinical trial
Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In…
NCT00359190 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00359190 |
|---|---|
| Title | Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer |
| Official title | A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients With Treatment- Naive Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib |
| Enrollment | 28 |
| Start date | Jun 29, 2004 |
| Primary completion | Jan 9, 2008 |
| Completion | Jan 9, 2008 |
| First posted | Aug 1, 2006 |
| Last update posted | Nov 13, 2017 |
| Countries | Israel, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: